Immunoprotein Diagnostic Testing Market Outlook 2031:
The global immunoprotein diagnostic testing market size was valued at USD 12.53 Billion in 2022 and is projected to reach USD 22.27 Billion by 2031, expanding at a CAGR of 6.6% during the forecast period 2023 - 2031. Immunoproteins are used as a target for immunological probes or treatments. Immunoprotein diagnostic testing is the process of determining the quantity of immunoproteins in the body in order to analyze diseases associated with specific proteins such as immunoglobulin and pre-albumin.
The COVID-19 pandemic has created a significant issue for all healthcare industry verticals, including the immunoprotein diagnostic testing market. The market is being dealing with emerging obstacles, such as intermittent supply chain events in the manufacturing, production and distribution of diagnostic kits and tests globally.
Furthermore, trade restrictions and a lack of human resources have restricted the delivery of these test kits to customers. However, the increased demand for these products for COVID-19 detection compensates for this negative impact.
Immunoprotein Diagnostic Testing Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of infectious and chronic diseases is estimated to drive the market growth.
- Rising geriatric population and an increase in demand for early diagnostic services are major factors fueling the growth of the market.
- Technical improvements in immunodiagnostic instruments and the introduction of novel automated systems are major factors expected to boost the growth of the immunoprotein diagnostic testing market in the coming years.
- Complex regulatory environment for the approval of numerous immunoprotein diagnostic tests can restrain the growth of the market.
- Ongoing development in condition-specific assays and tests and the necessity for early diagnosis can provide attractive opportunities for the market growth.
Scope of Immunoprotein Diagnostic Testing Market Report
The report of the global immunoprotein diagnostic testing market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
Attributes
|
Details
|
Report Title
|
Immunoprotein Diagnostic Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2022
|
Historic Data
|
2016 – 2021
|
Forecast Period
|
2023 – 2031
|
Segmentation
|
Types (C-reactive Protein Diagnostic Test, Complement System Protein Diagnostic Test, Pre-albumin Diagnostic Test, Haptoglobin Diagnostic Test, Immunoglobin Diagnostic Test, Free Light Chain Diagnostic Test, and Others) Applications (Autoimmune Testing, Allergy Testing, Oncology Testing, Toxicology Testing, and Others), Technology (Radioimmunoassay, Immunoturbidity Assay, Immunoprotein Electrophoresis, Enzyme-linked immunosorbent Assay, and Others)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
F. Hoffmann-La Roche Ag, Abcam PLC, Abbott Laboratories, Diasorin, Enzo Life Sciences, Randox Laboratories, Siemens, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, Ortho Clinical Diagnostics
|
Immunoprotein Diagnostic Testing Market Segment Insights
Based on types, the market can be divided into C-reactive protein diagnostic test, complement system protein diagnostic test, pre-albumin diagnostic test, haptoglobin diagnostic test, immunoglobin diagnostic test, free light chain diagnostic test, and others. The immunoglobulin diagnostics test segment is anticipated to hold a large market share during the forecast period.
This is due to the fact that they are widely used and allow healthcare providers to acquire information about a patient's immune system's functioning in autoimmune or infectious disorders. Immunoglobulin testing, however, are ineffective in particular situations, such as during chemotherapy or radiation therapy, and during ongoing blood transfusions or vaccines.
Oncology testing segment to account a significant market share
On the basis of applications, the market can be segregated into autoimmune testing, allergy testing, oncology testing, toxicology testing, and others. The oncology testing segment is anticipated to hold for a significant growth rate during the forecast period. Rising prevalence of cancer is estimated to drive the market growth.
Enzyme-linked immunosorbent assay segment to constitute a major market share
In terms of technology, the market can be segregated into radioimmunoassay, immunoturbidity assay, immunoprotein electrophoresis, enzyme-linked immunosorbent assay, and others. The enzyme-linked immunosorbent assay segment is expected to hold a major market share.
This was attributed to the increased use of immunoassays in cancer, point-of-care IVD testing, infectious disease testing, therapeutic medication level monitoring, and the development of novel biomarkers. The benefits of ELISA include a long shelf life and ease of use, which has led to growing acceptance of these tests in the academic and industrial sectors.
North America is expected to dominate the market
Based on regions, the market can be divided into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is anticipated to hold over 40% market share during the forecast period due to the increased demand for rapid diagnostic services to detect chronic diseases, the continuous trend of preventative healthcare, and the rise in the number of drug abuse and allergy instances.
Segments
By Types
- C-reactive Protein Diagnostic Test
- Complement System Protein Diagnostic Test
- Pre-albumin Diagnostic Test
- Haptoglobin Diagnostic Test
- Immunoglobin Diagnostic Test
- Free Light Chain Diagnostic Test
- Others
By Applications
- Autoimmune Testing
- Allergy Testing
- Oncology Testing
- Toxicology Testing
- Others
By Technology
- Radioimmunoassay
- Immunoturbidity Assay
- Immunoprotein Electrophoresis
- Enzyme-linked immunosorbent assay
- Others
By Regions
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
By Key Players
- F. Hoffmann-La Roche Ag
- Abcam PLC
- Abbott Laboratories
- Diasorin
- Enzo Life Sciences
- Randox Laboratories
- Siemens
- Thermo Fisher Scientific Inc
- Bio-Rad Laboratories, Inc
- Danaher Corporation
- Ortho Clinical Diagnostics
Competitive Landscape
The key players of the immunoprotein diagnostic testing market include F. Hoffmann-La Roche Ag, Abcam PLC, Abbott Laboratories, Diasorin, Enzo Life Sciences, Randox Laboratories, Siemens, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, Ortho Clinical Diagnostics, among others.
The key players are routing decision growth strategies such as expansion, mergers and acquisitions, partnerships, product launches, and collaborations in order to contribute to the market.